Newport Healthcare 2025 Treatment Outcomes
Newport Healthcare’s latest research shows that our comprehensive treatment model created transformative, lasting results for adolescents and young adults in both residential and outpatient care in 2025.
Newport Healthcare 2025 Treatment Outcomes
Newport Healthcare’s latest research shows that our comprehensive treatment model created transformative, lasting results for adolescents and young adults in both residential and outpatient care in 2025.
Who We Are
Newport Healthcare is the nation’s leading provider of behavioral healthcare for children, adolescents, and young adults struggling with high-acuity mood, anxiety, and co-occurring disorders.
How We Achieve Industry-Leading Results
Newport Healthcare uses a results-driven treatment model, facilitated by clinicians trained and supervised in evidence-based and empirically supported therapeutic modalities. Each patient receives individualized care.
At our residential and outpatient programs nationwide, our treatment teams incorporate a wide variety of specializations—clinical, medical, psychiatric, experiential, dietary, life skills, and academic—to create sustainable healing that changes the lives of young people and families.
What Our 2025 Outcomes Research Shows
Our data highlights the effectiveness of Newport Healthcare’s nationwide programs, showing that patients experienced measurable improvements, on average, in depression, anxiety, suicide risk, well-being, family attachment, general functioning, and other measures.
Independently reviewed by a third-party academic consultant, Newport’s 2025 research is evidence that our comprehensive treatment model creates transformative, lasting results for adolescents and young adults in both residential and outpatient care.
Click through the menu below to learn how we track outcomes, view our patient profiles, and see results across a range of measures.
How We Track Outcomes
In 2025, 2,971 adolescents and 1,217 young adults were in our Newport Academy and Newport Institute residential programs, and 962 adolescents and young adults were in our outpatient programs, including our Center for Families locations. For residential patients, surveys were administered at intake, week 3, and every two weeks following until discharge. For those in outpatient care, surveys were administered at intake, at day 21, and every 30 days following until discharge. Post-discharge surveys were sent to patients and families via email at 30, 90, and 180 days after treatment concluded.
The resulting data was analyzed by the Newport Healthcare Center for Research and Innovation, under the leadership of Senior Director Michael Roeske, PsyD.
The entire report was independently reviewed by Colin Walsh, MD, MA, Associate Professor, Department of Bioinformatics, Medicine, and Psychiatry at Vanderbilt University, who provided external approval of the analytic methods and conclusions presented.
“Newport Healthcare demonstrates clinical care that improves outcomes and well-being. The emphasis on measuring outcomes with validated metrics and transparency in results reporting are key components of this success.”
—Colin Walsh, MD, MA, Vanderbilt University
Data analysis included statistical significance testing, which is measured by a p value, indicating whether the research outcome cannot reasonably be attributed to the operation of chance or random factors rather than treatment. Effect size can be measured by Cohen’s d (0.2 is small, 0.5 is medium, and 0.8 is large), indicating whether there is a meaningful finding beyond statistical significance.
Patient Survey Data
Residential
| Timepoint | Intake | Week 3 | Week 5 | Week 7 | Week 9 | 30 Days Post-Discharge | 90 Days Post-Discharge | 180 Days Post-Discharge |
|---|---|---|---|---|---|---|---|---|
| # of Adolescent Surveys Completed | 2,419 | 1,892 | 1,460 | 1,009 | 475 | 248 | 185 | 165 |
| # of Young Adult Surveys Completed | 1,440 | 1,049 | 739 | 436 | 192 | 248 | 177 | 133 |
Outpatient
| Timepoint | Intake | Day 21 | Day 51 | Day 81 | 30 Days Post-Discharge | 90 Days Post-Discharge | 180 Days Post-Discharge |
|---|---|---|---|---|---|---|---|
| # of Adolescent Surveys Completed | 688 | 572 | 392 | 202 | 39 | 30 | 23 |
| # of Young Adult Surveys Completed | 196 | 134 | 78 | 30 | 17 | 9 | 10 |
OCD and Eating Disorders
| Screener | CY-BOCS – OCD Overall | CY-BOCS – Severe OCD | Y-BOCS – OCD Overall | Y-BOCS – Severe OCD | EDE-Q – Overall | EDE-Q – Clinically Significant |
|---|---|---|---|---|---|---|
| # of Patient Surveys Completed at Both Intake and Final Assessment | 38 | 25 | 74 | 57 | 280 | 49 |
For OCD outcomes, effect sizes were large for both adolescents (d = 1.275 for all patients, d = 1.593 for patients with severe OCD) and young adults (d = 1.292 for all patients, d = 1.371 for patients with severe OCD). EDE-Q changes were also statistically significant (p <.001), with a moderate effect size (d = .508).
Assessment Tools
Outcomes Measures
| Scale/ Screener | GAD-7 GAD-2 | PHQ-9 PHQ-2 | WHO-5 | ECR-RS | WAI-SR | CY-BOCS, Y-BOCS | EDE-Q |
|---|---|---|---|---|---|---|---|
| Domain | Anxiety | Depression | Well-Being | Family Attachment | Working Alliance with Therapist | OCD | Eating Disorders |
Symptomology Measures
| Scale/Screener | BHS | CATS | PC-PTSD-5 | CAGE-AID | FAD-GF |
|---|---|---|---|---|---|
| Domain | Substance use, school safety, sexual risk, suicide, self-harm, trauma, bullying | Probably PTSD (adolescents) | Probable PTSD (adults) | Probable substance use disorder | Family Functioning |
Limitations of the Data
- Attrition – Sample sizes decline over time and become especially small after discharge; respondents at later timepoints may differ systematically from the broader patient population.
- Response bias – Responses may differ systematically from patients’ actual experiences because of demand characteristics, recall difficulties, or tendencies toward extreme or neutral responding.
- Fixed timepoints – Assessments at weeks 3 and 5 or day 51 may underrepresent patients discharged earlier and may not capture the later treatment course of patients who remain longer.
- Single-informant design – Most reported outcomes rely on patient self-report, with limited corroboration from caregivers, clinicians, or behavioral indicators.
- Aggregation – Overall averages may obscure meaningful differences across sites, diagnoses, demographic groups, levels of acuity, and clinical complexity.
- Post-discharge attribution – Outcomes following discharge may reflect subsequent treatment, supports, or stressors, making conclusions about the durability of effects tentative.
- No comparison group – Without a comparable untreated or alternatively treated group, observed improvement cannot be attributed exclusively to treatment.
Patient Diagnoses at Intake
In 2025, depression was the most common primary diagnosis among Newport’s adolescent and young adult patients, followed by post-traumatic stress disorder (PTSD) for adolescents and bipolar disorders for young adults. About half of patients had a secondary diagnosis of anxiety.
Rather than focusing solely on diagnoses, Newport treatment takes a “whole-person” approach that recognizes and addresses each individual’s multifaceted presentation, history, and symptomology. Through individually tailored treatment plans, ongoing family involvement, and industry-leading staff-to-client ratios, we achieve powerful patient engagement that leads to long-lasting results.
Primary Diagnosis
Secondary Diagnosis
Patient Profiles
Consistent with past years, about half of Newport’s 2025 patients identified as female, around 40% as male, and the remaining percentage as trans or genderqueer/gender-nonconforming. About half identified as heterosexual and the remaining percentage as bisexual, gay, lesbian, pansexual, or asexual. Symptom acuity among LGBTQ+ patients was comparable to that of straight and cisgender patients, and both groups, on average, improved at similar rates.
Gender Identity
Sexual Orientation
Risk Factors & Symptomology
To deepen our insight into our patients’ experiences and challenges, our assessments ask patients about their exposure to various risk factors, including trauma, bullying, and family conflict, and their engagement in potentially self-destructive behaviors, such as substance use. We also ask about their device use and their potential suicide risk.
of young adult residential patients have a probable substance use problem
of adolescents in outpatient care felt life was not worth living
1 in 3
Patients were likely to have PTSD
1 in 3
Patients spent 7+ hours a day on
screens for entertainment
of adolescent residential patients report not getting along well with family
of all adolescent patients report experiencing verbal bullying
Depression & Suicide Risk
Most Newport patients in 2025 had a primary diagnosis of depression. We looked at improvements in patients who reported moderate to severe depressive symptoms on the PHQ-9 at intake.
After just three weeks at Newport, residential patients’ scores had dropped into the moderate range, on average, and by week 5, the average score was at mild levels. For patients in outpatient care and for those with severe depression (20 and above), symptoms dropped to moderate levels, on average.
Newport treats depression through multidisciplinary care that guides teens and young adults to process underlying trauma, repair relationships, and build resilience and self-worth.
Patient Health Questionnaire-9 (PHQ-9) Levels
- 20–27: Severe
- 15–19: Moderately Severe
- 10–14: Moderate
- 5–9: Mild
Depression
Severe Depression
Improvements in depression and severe depression were statistically significant (p <.001), and outcomes show medium to large effect size changes, indicating that Newport treatment had a meaningful impact on patients’ symptoms and experience. See Appendix for details.
TMS for Treatment-Resistant Depression
For patients with severe depression that has not responded to other forms of treatment, Newport offers Transcranial Magnetic Stimulation (TMS) through our PrairieCare division in Minnesota. TMS is an FDA-approved treatment approach that targets specific parts of the brain with magnetic pulses to help regulate mood for people with depression.
In 2025, 178 patients finished a complete course of TMS at one of PrairieCare’s two TMS clinics. More than half of those patients experienced 50% improvements in their depression symptoms, according to the PHQ-9. Average starting PHQ-9 score for this group was 16.5 (moderately severe) and average ending score was 8.7 (mild).
Suicide Risk
Newport assesses suicide risk by surveying patients on their suicidal thoughts, plans, and motivation to live. Over the course of treatment, the percentage of patients reporting these symptoms dropped by more than 50% across both age groups and in both levels of care.
Therapeutic Alliance
Therapeutic alliance—the sense of trust, connection, and collaboration between patient and therapist—is key to patient improvement.
Patients reported high working alliance at week 3, agreeing with statements such as “My therapist appreciates me,” “We agree on the important work to be done,” and “We work together on goal-setting.”
Working alliance scores further improved by week 5 (average score of 48 on the WAI-SR scale, which ranges from 0–60). These results show that Newport’s patients generally feel understood, respected, and liked by their therapists.
Anxiety & Traumatic Distress
In tracking anxiety outcomes, we measured improvements in patients who reported elevated symptoms of anxiety (moderate to severe) at intake. On average, patients’ anxiety scores fell from severe to moderate levels by week 3, and to mild levels by week 5 of residential treatment or day 51 of outpatient care. For those with severe anxiety (a score of 15 and above), symptoms dropped to moderate levels by week 5/day 51.
To address anxiety, we use modalities including Cognitive Behavioral Therapy, Dialectical Behavioral Therapy–informed skills, and Acceptance and Commitment Therapy, to help patients reframe negative thoughts, build distress tolerance, and develop positive coping skills.
Generalized Anxiety Disorder-7 (GAD-7) Levels
- 15–21: Severe
- 10–14: Moderate
- 5–9: Mild
Anxiety
Severe Anxiety
Improvements in anxiety and severe anxiety were statistically significant (p <.001), and outcomes show medium to large effect size changes, indicating that Newport treatment had a meaningful impact on patients’ symptoms and experience. See Appendix for details.
Traumatic Distress
The BHS-Trauma subscale is used to assess distress related to traumatic experiences. The scale contains four items that assess current distress:
- Nightmares
- Avoiding reminders of past trauma
- Feeling on guard
- Feeling numb and detached
At intake, close to half of patients in residential care and 30–40% in outpatient care reported experiencing these symptoms over the past two weeks. All symptoms decreased, on average, by week 5/day 51.
“I had been to different treatment centers before, and not one of them had given me what I needed. Newport didn’t just try to fix me like the other programs did—they listened to me, processed with me, and made me feel important.”
—Dylan C., alum
Well-Being & Family Attachment
Newport patients generally reported poor well-being at intake, which improved to the “well” range by week 5 of residential treatment or day 51 of outpatient care. Patients with depression or anxiety reported even lower well-being at intake, which also increased over time to the “well” range.
Our individualized treatment creates meaningful change for young people, allowing them to feel seen and supported within a caring community.
WHO-5 Well-Being Index Levels
- 13–25: Well
- 8–12: Poor Well-Being
- 0–7: Likely Depression
Overall Well-Being
Individual Well-Being Improvements for Patients with Depression
The percentage of patients reporting improvements in various aspects of well-being shows the positive impact of treatment on patients’ state of mind, day-to-day engagement with life, and overall sense of wellness.
Individual Well-Being Improvements for Patients with Anxiety
Family Attachment
Newport’s family-focused treatment model leverages Attachment-Based Family Therapy (ABFT) to rebuild trust and connection between patients and family members. To measure the impact of ABFT throughout treatment, patients are surveyed using the ECR-RS, which asks to report on how securely attached they are to a primary and secondary attachment figure (e.g., mother, father, stepparents, grandparents, etc.).
In reporting on parental attachment, patients rate their agreement with statements including:
- It helps to turn to this person in times of need
- I find it easy to depend on this person
- I don’t feel comfortable opening up to this person
- I’m afraid that this person may abandon me
At week 5 or residential care and day 51 of outpatient treatment, patients report improvements in attachment with both primary and secondary attachment figures.
Academics
To set students up for success after discharge, Newport uses an accredited academic curriculum for adolescents in our residential treatment and Partial Hospitalization Programs.
Results from the Newport Academic Scale show that patients report stronger motivation and better study skills at week 3 compared to intake, with further improvements at week 5.
OCD & Eating Disorders
Obsessive-Compulsive Disorder (OCD)
Newport provides specialized residential programming for OCD and related disorders. On average, adolescent and young adult patients in our OCD programs reported severe OCD at intake.
By the final assessment, patients reported moderate symptoms. These changes were statistically significant (p <.001), with large effect sizes between admission and the final assessment for all groups.*
Patients in our OCD-specific programs on the East and West Coasts receive 4.5 hours daily of Exposure and Response Prevention (ERP) therapy, the gold standard treatment for the disorder. We incorporate family therapy, CBT, and other modalities to address co-occurring disorders and common issues that occur alongside OCD, such as social anxiety, body dysmorphia, and other conditions.
Yale-Brown Obsessive Compulsive Scale (Y-BOCS) and Children’s Y-BOCS (for ages 6–17)
- Subclinical: 0–7
- Mild: 8–15
- Moderate: 16–23
- Severe: 24–31
- Extreme: 32–40
OCD
Severe OCD
* Statistical significance testing is measured by a p value, indicating whether the research outcome cannot reasonably be attributed to chance or random factors rather than treatment. Effect size indicates that Newport treatment had a meaningful impact on patients’ symptoms and daily experience. See more details in the Appendix.
Eating Disorders
Patients who are admitted to Newport with a history of eating disorders or current disordered eating symptoms require a nutrition evaluation by a registered dietician and are asked to fill out the EDE-Q.
On average, adolescent and young adult patients with disordered eating symptoms reported a probable eating disorder at intake, and experienced statistically significant improvements during treatment in their attitudes and behaviors around food, weight, and shape.
Eating Disorder Examination Questionnaire (EDE-Q) Levels
- Non-clinical: 0–1.59
- Probable ED: 1.6–3.99
- Severe: 4–6
By the final assessment, patients were in the non-clinical range. For patients with severe symptoms at intake (EDE-Q score of 4 or more), levels dropped into the moderate range over the course of treatment.
Our specialized residential treatment for eating disorders provides both dietary and clinical care, delivered by a team that includes medical doctors, psychiatrists, nurses, therapists, board-registered dietitians, certified eating disorder specialists, and more.
Post-Discharge Results
General Functioning
Our surveys include questions asking patients about their general functioning across various areas of life. General functioning is defined as an individual’s ability to cope with everyday demands. At intake and again 30 days post-discharge, patients used a scale of 0–10 to indicate how they had been doing over the past four weeks across six domains.
In the post-discharge survey, our alumni reported higher functioning in all domains, reflecting Newport’s focus on helping patients build healthy coping skills, authentic relationships, and a sense of purpose and optimism.
Post-Discharge Outcomes
Post-discharge data captures how patients are functioning after they leave our care, offering insight into the durability of treatment gains. Collecting and analyzing this information helps us strengthen our ability to design programs that promote lasting well-being and reduces the likelihood of relapses or readmission.
Survey results show that six months after discharge, patients generally maintained improvements made in Newport treatment.
The Newport Healthcare Experience
The Newport experience spans every aspect of the treatment journey, from the admissions process and customer service to quality of care and support after discharge. In 2025, our patients, their parents, and referring professionals all reported high satisfaction, on average, with Newport’s quality of care, treatment services, and staff.
Referring Professionals
Will refer to Newport again
Reported that their clients received exceptional treatment
Patients
9 in 10
Young adults felt welcomed and accepted at Newport
8 in 10
Patients felt that Newport staff took the time to understand them
Family
Felt that staff paid attention to their family’s needs and goals
Would recommend Newport to other families who need help
The Alumni Experience
Newport’s Alumni Program supports young people to maintain recovery through sharing challenges, accepting and encouraging one another, and validating each other’s achievements and progress. In 2025:
- 4,340 alumni and family members attended 16 weekly online support groups and 3 monthly groups
- 17,975 alumni and family members used the Newport app, our portal for accessing resources
- 536 alumni and family attended in-person reunions in California, Connecticut, Washington, and Virginia
- 100% of alumni parents surveyed shared that it was helpful knowing they could connect to an alumni team member anytime post-discharge
The PrairieCare Experience
At PrairieCare, our division in Minnesota, we measure patient satisfaction using the Net Promoter Score (NPS), an industry-standard measurement that surveys patients about their experience related to admissions, consistency of care, communication, and support from staff. PrairieCare’s overall NPS in 2025, across treatment locations, was 41.9, exceeding the national NPS benchmark by 7.4 points. We also collected the following data:
of PrairieCare patients reported they received excellent customer service
of referring professionals report they will refer to PrairieCare again
Download a Summary
Get our flyer with an overview of our treatment outcomes.
A Message from Our CEO
Our exceptional 2025 outcomes reflect the unwavering dedication of our multidisciplinary teams, whose expertise and compassion set us apart in the industry. These results showcase the tangible difference we make in the lives of those we serve—the young people and families whose futures are brighter because of the healing we help inspire.
Brian Setzer, CEO
Newport Healthcare
We Are Here to Help
If you are a healthcare provider, educator, or employer who would like to make a referral, we’re here to support you. If you’re seeking treatment for yourself or a loved one, we can help you get started on the healing journey. Our Clinical Outreach and Admissions teams are standing by, ready to guide you toward the right care.
